Over 1,400 Lawsuits Pending in Federal Court Against Manufacturers of Pradaxa®
Since August, 79 lawsuits have been filed in federal court against the manufacturers of Pradaxa®. These lawsuits have been added to the Multidistrict Litigation In re: Pradaxa® (Dabigatran Etexilate) Products Liability Litigation (MDL 2385), which is currently pending in the United States District Court for the Southern District of Illinois before the Honorable Chief Judge David R. Herndon. The number of lawsuits joined in MDL 2385 increased from 1,343 in August to 1,422 as of September 15, 2013.
Pradaxa® is a relatively new blood thinning medication manufactured by the German-based pharmaceutical company Boehringer Ingelheim. It was approved by the FDA in 2010 as a blood thinning medication used to lower the chance of stroke in patients with non-valvular atrial fibrillation (AF or A-fib). In 2011, the U.S. Food and Drug Administration initiated a formal investigation into serious bleeding events associated with Pradaxa®. Unlike other blood thinning medications, such as Warfarin, there is no known reversal agent or antidote for Pradaxa®. As a result, Pradaxa® may cause excessive and serious bleeding that sometimes leads to death.
A March 2012 article published in the New England Journal of Medicine pointed out that the lack of an effective reversal agent is an important concern. In September 2012, the Journal of the American College of Cardiology published a multicenter prospective study, which concluded that patients using Pradaxa® experience a significant increase in the risk of bleeding complications compared with patients treated using warfarin therapy. As recently as September of this year, a study published in the New England Journal of Medicine revealed that a Pradaxa® clinical trial had to be aborted due to health risks posed for study participants using the drug.
Schlichter, Bogard & Denton, LLP are leaders in the national Pradaxa® Multidistrict Litigation (MDL 2385). Partner Roger Denton has been appointed by Judge Herndon to serve as Plaintiffs’ Co-Lead Counsel in the Multidistrict Litigation. If you or a loved one have experienced complications from Pradaxa®, please contact the experienced attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.
Legal Disclaimer: The choice of a lawyer is an important decision and should not be based solely on advertisements.